Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) by Domain and Individual Items (P3.130)

Conclusions:A generally favorable descriptive effect for edaravone was observed during posthoc assessment of the ALSFRS-R by domain and individual items.Study Supported by: MTPC was responsible for funding and conduct of the study. MTDA was responsible for executing this analysis.Disclosure: Dr. Palumbo has received personal compensation for activities with Mitsubishi Tanabe as an employee. Dr. Palumbo holds stock options in Actelion Clinical Research, Inc., in which his spouse is a full-time pharmaceutical researcher and receives stock options as partial compensation for work performed. Dr. Takei has received personal compensation for activities with Mitsubishi Tanabe as an employee. Dr. Tsuda has received personal compensation for activities with Mitsubishi Tanabe. Dr. Liu has received personal compensation for activities with Mitsubishi Tanabe as an employee.
Source: Neurology - Category: Neurology Authors: Tags: Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron Disease I Source Type: research